Search

Your search keyword '"ANGIOTENSIN receptors"' showing total 74 results

Search Constraints

Start Over You searched for: Descriptor "ANGIOTENSIN receptors" Remove constraint Descriptor: "ANGIOTENSIN receptors" Region united states Remove constraint Region: united states
74 results on '"ANGIOTENSIN receptors"'

Search Results

1. Sparsentan in immunoglobulin A nephropathy: a profile of its use.

2. Recent Advances in the Treatment and Management of Heart Failure: Expert Perspectives on the Role of New and Emerging Therapies.

3. Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension.

4. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.

5. Adverse Drug Effects Across Patients With Heart Failure: A Systematic Review.

6. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.

7. Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer.

8. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.

9. Variability of discharge medical therapy for secondary prevention among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in the United States.

10. The Ecology of Antihypertensives in the United States, 1997–2017.

11. Effect of Prescription Tongxin on Endothelial Progenitor Cells in Peripheral Blood.

12. Antihypertensive agent utilization patterns among patients with uncontrolled hypertension in the United States.

13. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.

14. Association Between HEDIS Performance and Primary Care Physician Age, Group Affiliation, Training, and Participation in ACA Exchanges.

15. Understanding and Preventing ( -Nitrosodimethylamine) NDMA Contamination of Medications.

16. Residual risk for coronary heart disease events and mortality despite intensive medical management after myocardial infarction.

18. Renin–angiotensin system blockade after transcatheter aortic valve replacement (TAVR) improves intermediate survival.

19. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.

20. No longer failing to treat heart failure: A guideline update review.

21. Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States.

22. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.

23. Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality.

24. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

25. Comparative effectiveness of antihypertensive drugs in nondiabetic patients with hypertension: A population-based study.

26. Medical therapy following hospitalization for heart failure with reduced ejection fraction and association with discharge to long-term care: a cross-sectional analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) population.

27. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk.

28. Angiotensin-Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi-Ethnic Study of Atherosclerosis Lung Study.

29. Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans.

30. ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.

31. Renin-Angiotensin System Inhibition and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure.

32. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial.

33. The Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients With Diabetes.

34. Adherence to Metformin, Statins, and ACE/ARBs Within the Diabetes Health Plan (DHP).

35. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis.

36. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.

37. Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [3H]dopamine and [3H]norepinephrine release.

38. Ramipril and Telmisartan Exhibit Differential Effects in Cardiac Pressure Overload-Induced Hypertrophy Without an Additional Benefit of the Combination of Both Drugs.

39. Current treatment of heart failure in the USA.

40. Angiotensin receptor blockers on the formularies of Medicare drug plans.

41. Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002.

42. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.

43. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.

44. Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls.

45. The 2014 hypertension guidelines: Processing the information.

46. Acute Myocardial Infarction Cohorts Defined by Versus Diagnosis-Related Groups: Analysis of Diagnostic Agreement and Quality Measures in an Integrated Health System.

47. FROM THE JOURNALS.

48. Patterns of Antihypertensive Drug Utilization among US Adults with Diabetes and Comorbid Hypertension: The National Health and Nutrition Examination Survey 1999-2014.

49. Abstract 11998: Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy is Not Associated With Patient-Reported Peripheral Artery Disease Specific Health Status: Data From the PORTRAIT Study.

50. ABFM'S HEART FAILURE SELF-ASSESSMENT MODULE SIMULATION ACTIONS VIS-À-VIS GUIDELINE RECOMMENDATIONS.

Catalog

Books, media, physical & digital resources